iX Biopharma issues 2.92 million new shares after warrant exercise
SGX Filings
Jul 14
iX Biopharma Ltd (42C) said on Jul, 14 2026 that it has allotted and issued 2.92 million new ordinary shares following the exercise of warrants priced at 0.06 Singapore dollars each.
The issuance comprises 1.00 million shares to Director Albert Ho Shing Tung and 15,301 shares to Centrum Capital Pte Ltd, a company in which Ho is deemed to have an interest.
As a result, the company’s outstanding share capital has risen to 1.08 billion shares from 1.07 billion shares.
To date, 41.27 million warrants, representing 71.76% of the series, have been exercised, leaving 16.24 million warrants outstanding. The remaining warrants will expire at 5:00 p.m. on Jul, 17 2026 if not exercised.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.